Histamine and Bradykinin Pharmacology

Correct Answer

C — Promethazine

Rationale

Promethazine is a phenothiazine-derived first-generation H1 antihistamine. Its phenothiazine structure confers pronounced antiemetic and sedative properties alongside its antihistaminic activity, making it useful for motion sickness and postoperative nausea. Diphenhydramine, hydroxyzine, and chlorpheniramine are first-generation H1 antihistamines from different structural classes — none are phenothiazine derivatives.

Correct Answer

A — Cetirizine

Rationale

Cetirizine is the active metabolite of hydroxyzine, a first-generation H1 antihistamine. Loratadine is a second-generation agent whose active metabolite is desloratadine. Fexofenadine is the active metabolite of terfenadine, a first-generation agent withdrawn due to cardiac toxicity. Desloratadine is the active metabolite of loratadine, not of hydroxyzine.

Correct Answer

D — Fexofenadine

Rationale

Fexofenadine is the least sedating second-generation H1 antihistamine. Its negligible central nervous system penetration results from low lipophilicity and robust P-glycoprotein-mediated efflux at the blood-brain barrier. Cetirizine is a second-generation agent but is slightly more sedating than loratadine or fexofenadine due to modestly greater central nervous system penetration. Loratadine is non-sedating at standard doses but is not considered the least sedating agent in the class. Hydroxyzine is a first-generation agent with pronounced sedation.

Correct Answer

B — Levocetirizine

Rationale

Levocetirizine is the pharmacologically active enantiomer of cetirizine and is available at half the standard cetirizine dose with a comparable clinical profile. Desloratadine is the active metabolite of loratadine, not an enantiomer of cetirizine. Fexofenadine is the active metabolite of terfenadine. Loratadine is an independent second-generation antihistamine whose active metabolite is desloratadine.

Correct Answer

A — Physostigmine

Rationale

Physostigmine is a cholinesterase inhibitor that crosses the blood-brain barrier, making it the appropriate antidote for severe central nervous system anticholinergic toxicity such as that produced by diphenhydramine overdose. Neostigmine is also a cholinesterase inhibitor but does not cross the blood-brain barrier and therefore cannot reverse central nervous system anticholinergic effects. Naloxone is an opioid receptor antagonist used to reverse opioid toxicity. Flumazenil is a benzodiazepine receptor antagonist used to reverse benzodiazepine-induced sedation.

Correct Answer

C — Loratadine

Rationale

Loratadine undergoes extensive hepatic first-pass metabolism to its active metabolite desloratadine. Because its elimination is hepatic rather than renal, loratadine does not require dose adjustment in patients with renal impairment. Cetirizine and levocetirizine are eliminated largely unchanged by the kidney and require dose reduction in significant renal impairment. Fexofenadine is eliminated primarily unchanged in feces and urine; while it requires caution in severe renal impairment, it is not classified as a hepatically eliminated agent in the same way loratadine is.

Correct Answer

B — Second-generation agents are substrates for P-glycoprotein, an efflux transporter on brain endothelial cells that actively pumps them back into the bloodstream

Rationale

P-glycoprotein is an adenosine triphosphate-dependent efflux transporter expressed at high density on the luminal surface of brain endothelial cells. Second-generation antihistamines are substrates for this transporter: even when a molecule diffuses into the endothelial cell, P-glycoprotein actively expels it back into the bloodstream, preventing central nervous system accumulation. Reduced lipophilicity also contributes by limiting passive diffusion, but P-glycoprotein efflux is the primary and more important mechanism. Paracellular diffusion across tight junctions is blocked for virtually all drugs regardless of generation. Plasma protein binding slows distribution but does not prevent central nervous system entry. Cytochrome P450 enzymes at the blood-brain barrier are not the mechanism of central nervous system exclusion for antihistamines.

Correct Answer

D — Physostigmine inhibits cholinesterase and crosses the blood-brain barrier, raising central nervous system acetylcholine levels and reversing muscarinic receptor blockade

Rationale

Diphenhydramine overdose produces anticholinergic toxicity by blocking muscarinic receptors throughout the body, including in the central nervous system. Physostigmine is effective because it inhibits acetylcholinesterase — the enzyme that degrades acetylcholine — and, unlike neostigmine, it crosses the blood-brain barrier. The resulting increase in synaptic acetylcholine concentrations allows acetylcholine to compete with and displace diphenhydramine from central nervous system muscarinic receptors, reversing agitation, delirium, and other central anticholinergic manifestations. Physostigmine does not bind H1 receptors. P-glycoprotein efflux is not its mechanism of action. Physostigmine is an indirect cholinomimetic — it works by preserving endogenous acetylcholine, not by acting as a direct muscarinic agonist.

Correct Answer

A — Cetirizine is eliminated primarily unchanged by the kidney, so reduced renal clearance leads to drug accumulation

Rationale

Cetirizine is excreted largely unchanged in the urine. When renal function is impaired, the rate of cetirizine clearance falls proportionally, and the drug accumulates to higher plasma concentrations than intended at standard doses. Dose reduction restores appropriate exposure. This contrasts with loratadine, which undergoes hepatic metabolism and does not require renal dose adjustment. Cetirizine does not undergo extensive hepatic metabolism — minimal conversion occurs before renal excretion. Cetirizine does not inhibit its own renal tubular secretion. P-glycoprotein in the kidney mediates drug secretion rather than reabsorption, and reduced P-glycoprotein activity would decrease secretion rather than explaining accumulation through increased reabsorption.

Correct Answer

C — Fruit juice inhibits an intestinal uptake transporter that fexofenadine depends on for absorption, reducing the amount of drug that enters the intestinal epithelium

Rationale

Fexofenadine is a substrate for an intestinal uptake transporter — an organic anion transporting polypeptide — that facilitates its absorption across the intestinal epithelium. Grapefruit juice, orange juice, and apple juice contain compounds that inhibit this transporter, reducing fexofenadine uptake and its oral bioavailability. The practical management is straightforward: take fexofenadine with water rather than any fruit juice. This interaction is distinct from the grapefruit-cytochrome P450 interaction seen with other drugs. Fexofenadine undergoes minimal hepatic metabolism, so cytochrome P450 induction is not relevant here. Gastric pH changes do not account for this interaction. The interaction involves inhibition of an uptake transporter, not activation of an efflux transporter such as P-glycoprotein.

Correct Answer

B — First-generation antihistamines cross the blood-brain barrier and suppress central nervous system activity; combining them with other central nervous system depressants produces additive depression

Rationale

First-generation antihistamines are lipophilic and cross the blood-brain barrier, where they suppress central nervous system arousal by blocking H1 receptors on histaminergic neurons of the tuberomammillary nucleus. This central nervous system depressant effect is additive with other agents that depress the central nervous system — including alcohol, opioids, and benzodiazepines — and the combination can produce dangerous respiratory depression and psychomotor impairment beyond what any single agent would cause alone. Second-generation antihistamines, which do not appreciably enter the central nervous system, do not carry this same interaction risk. First-generation antihistamines are not clinically relevant inhibitors of cytochrome P450 enzymes. Plasma protein displacement and Gamma-aminobutyric acid type A receptor sensitization is not an established mechanism for this class interaction.

Correct Answer

D — First-generation antihistamines have significant antimuscarinic activity that contributes to cognitive impairment, confusion, falls, and urinary retention in elderly patients

Rationale

First-generation antihistamines block muscarinic acetylcholine receptors throughout the body and in the central nervous system. In elderly patients, who have reduced cholinergic reserve as part of normal aging, this antimuscarinic burden produces a disproportionate risk of cognitive impairment, acute confusion, falls, and urinary retention. These adverse effects are compounded when multiple anticholinergic medications are prescribed concurrently. Second-generation antihistamines have negligible antimuscarinic activity and are the preferred alternative when antihistamine therapy is needed in older adults. The Beers Criteria recommendation is driven by pharmacodynamic vulnerability — the elderly brain and bladder are more sensitive to muscarinic blockade — not by pharmacokinetic changes in drug accumulation or enzyme inhibition.

Correct Answer

A — First-generation agents provide combined H1 blockade in the vestibular apparatus and muscarinic blockade in the vomiting center, both of which contribute to antiemetic efficacy

Rationale

Motion sickness involves both histaminergic and cholinergic signaling in the vestibular system and the vomiting center. First-generation antihistamines are effective because they block both H1 receptors in the vestibular apparatus and muscarinic receptors in the vomiting center. Second-generation antihistamines provide peripheral H1 blockade but do not enter the central nervous system in meaningful concentrations and have negligible antimuscarinic activity — they therefore lack both central components required for motion sickness prophylaxis. The advantage of first-generation agents here is not superior H1 potency but the combination of central H1 and muscarinic blockade that second-generation agents cannot provide. Promethazine is particularly effective for motion sickness because its phenothiazine structure confers additional dopamine receptor blockade at the chemoreceptor trigger zone, though this is an ancillary mechanism rather than the primary explanation for the class preference. First-generation antihistamines are not classified by active antiemetic metabolites.

Correct Answer

C — Incomplete maturation of central nervous system inhibitory systems in young children allows H1 blockade to produce disinhibition and excitation rather than sedation

Rationale

In young children, central nervous system inhibitory pathways are not yet fully mature. When first-generation antihistamines block H1 receptors and muscarinic receptors in the central nervous system, the result in this immature context can be disinhibition — the removal of inhibitory tone — rather than sedation, producing restlessness, irritability, and hyperactivity. This paradoxical response is not predictable from dose alone and is a recognized clinical hazard. Promethazine is contraindicated in children under two years of age specifically because of the risk of fatal respiratory depression. Pharmacokinetic differences in body surface area or stimulant metabolite production are not the established explanation for paradoxical excitation. The rebound histamine release hypothesis is not the accepted mechanism.

Correct Answer

D — Loratadine, because hepatic elimination means renal clearance does not affect drug exposure and no dose adjustment is required

Rationale

Loratadine undergoes extensive hepatic first-pass metabolism to its active metabolite desloratadine. Because the kidney plays no meaningful role in its elimination, reduced glomerular filtration rate does not affect loratadine drug exposure, and no dose adjustment is required even in moderate to severe renal impairment. Cetirizine and levocetirizine are eliminated largely unchanged by the kidney; in a patient with an estimated glomerular filtration rate of 32 mL/min/1.73 m², cetirizine and levocetirizine would accumulate at standard doses and require dose reduction. Fexofenadine is excreted primarily unchanged in feces and urine; it is less hepatically metabolized than loratadine and requires caution in severe renal impairment. When a patient with renal impairment asks specifically about an antihistamine requiring no renal dose adjustment, loratadine is the correct choice.

Correct Answer

B — Loratadine, because it is a second-generation H1 antihistamine with negligible antimuscarinic activity and minimal central nervous system penetration

Rationale

All first-generation H1 antihistamines — including diphenhydramine, promethazine, hydroxyzine, and chlorpheniramine — appear on the Beers Criteria list of medications to avoid in older adults because of their antimuscarinic burden and central nervous system penetration. In elderly patients with reduced cholinergic reserve, even agents considered lower-potency within the first-generation class carry meaningful risks of confusion, falls, and urinary retention. The appropriate switch is to any second-generation antihistamine — loratadine, cetirizine, or fexofenadine — which provide equivalent peripheral H1 blockade without meaningful central nervous system entry or antimuscarinic activity. Promethazine, hydroxyzine, and chlorpheniramine are all first-generation agents and are not appropriate substitutes in this context.

Correct Answer

A — Fexofenadine, because it undergoes minimal hepatic metabolism and is excreted largely unchanged, avoiding dependence on hepatic function for elimination

Rationale

Fexofenadine undergoes minimal hepatic metabolism and is eliminated primarily unchanged in feces and urine. In a patient with hepatic cirrhosis and reduced synthetic function, fexofenadine is the preferred second-generation antihistamine because its clearance does not depend on hepatic metabolic capacity. Loratadine requires hepatic first-pass metabolism to its active metabolite desloratadine — in the setting of cirrhosis with reduced hepatic function, this conversion may be impaired and drug exposure unpredictable. While cetirizine and levocetirizine are renally eliminated and avoid hepatic metabolism, their renal clearance does not make them superior choices here compared to fexofenadine, whose minimal metabolism profile is the most straightforward fit for hepatic impairment. Levocetirizine being an enantiomer of cetirizine does not reduce hepatic metabolic burden, as neither agent undergoes substantial hepatic metabolism to begin with.

Correct Answer

C — Promethazine is contraindicated in children under two years due to the risk of fatal respiratory depression, which has been reported even at recommended doses

Rationale

Promethazine carries a black box contraindication for use in children under two years of age because of documented cases of fatal respiratory depression, including deaths reported at doses within the recommended range. The immature respiratory control systems in this age group appear to confer heightened sensitivity to the respiratory depressant effects of promethazine. This risk is distinct from the paradoxical excitation seen in older children with first-generation antihistamines. Lethargy and respiratory distress in an 18-month-old after promethazine exposure should prompt emergency evaluation. Hepatic enzyme immaturity and renal tubular secretion differences do not explain this specific safety signal. H1 receptor density in respiratory epithelium is not the basis for this contraindication.